MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Tardive dyskinesia(TD)"

  • MDS Virtual Congress 2020

    Belly dancer’s dyskinesia due to prochlorperazine

    L. Cavdar, S. Ajasin, S. Woolf, R. Fekete (Valhalla, NY, USA)

    Objective: We aim to present a case report of abdominal wall dyskinesia as a tardive syndrome of prochlorperazine. Background: The clinical presentation of involuntary choreiform…
  • MDS Virtual Congress 2020

    Real-World Evaluation of Patient Characteristics and Disease Management in Long-Term Valbenazine Treatment in Adults with Tardive Dyskinesia

    E. Goldberg, C. Yonan, N. Longo, H. Cratty, M. Nicosia, J. Sampalis, T. Carmack, S. Siegert, A. Angelov (San Diego, CA, USA)

    Objective: To assess the clinical characteristics and overall disease management of adult patients receiving long-term valbenazine treatment for tardive dyskinesia (TD) in a real-world setting.…
  • MDS Virtual Congress 2020

    Patient Perspective of Tardive Dyskinesia: Results from a Social Media Listening Study

    L. Lundt, M. Farrar, E. Franey, C. Yonan (San Diego, CA, USA)

    Objective: To use social media listening (SML) to understand the impact of symptoms on patients with assumed/self-reported tardive dyskinesia (TD). Background: TD is a persistent…
  • MDS Virtual Congress 2020

    Real-World Use and Impact of VMAT2 Inhibitors in Patients with Tardive Dyskinesia

    L. Lundt, E. Franey, C. Yonan (San Diego, CA, USA)

    Objective: To describe symptom impact and treatment outcomes in patients prescribed vesicular monoamine 2 (VMAT2) inhibitors for the treatment of tardive dyskinesia (TD). Background: TD,…
  • MDS Virtual Congress 2020

    Comparison of Safety and Tolerability of Deutetrabenazine (DTBZ) During Titration and Maintenance in Patients With Tardive Dyskinesia (TD)

    K. Anderson, H. Fernandez, H. Barkay, A. Wilhelm, N. Chaijale, A. Send, J.M Savola, M. Gordon (Washington, DC, USA)

    Objective: To compare safety of DTBZ in titration vs maintenance using data from two 12-wk placebo (PBO)-controlled studies (ARM-TD and AIM-TD) and an open-label extension…
  • MDS Virtual Congress 2020

    Real-World Deutetrabenazine Dosing Patterns in Patients With Huntington’s Disease or Tardive Dyskinesia

    R. Ayyagari, A. Wilhelm, J. Alexander, N. Chaijale, V. Garcia-Horton, F. Devine, B. Carroll (Boston, MA, USA)

    Objective: To evaluate real-world treatment patterns and adherence to deutetrabenazine (DTBZ) in patients with Huntington’s disease (HD) or tardive dyskinesia (TD). Background: DTBZ is a…
  • 2019 International Congress

    An Experimental Study to Assess the Professional and Social Consequences of Tardive Dyskinesia

    R. Ayyagari, D. Goldschmidt, F. Mu, S. Caroff, B. Carroll (Boston, MA, USA)

    Objective: Evaluate the impact of orofacial tardive dyskinesia (TD) symptoms on the professional and social lives of patients with TD. Background: TD, a movement disorder…
  • 2019 International Congress

    Clinically Relevant Changes in AIMS Based on Clinical and Patient Global Impression of Change in Patients With Tardive Dyskinesia Treated with Deutetrabenazine

    H. Barkay, A. Wilhelm, M. Wieman, M. Gordon, R. Hauser, JM. Savola (Netanya, Israel)

    Objective: To assess clinically relevant reductions with treatment of deutetrabenazine in abnormal involuntary movements in patients with tardive dyskinesia (TD), as evidenced by correlation between…
  • 2019 International Congress

    Long-Term Outcomes in Patients with Tardive Dyskinesia who Were Early Responders with Valbenazine

    S. Factor, C. Comella, S. Marder, J. Burke, K. Farahmand, S. Siegert (Atlanta, GA, USA)

    Objective: To assess the long-term outcomes of once-daily valbenazine (VBZ) on tardive dyskinesia (TD) using a formal assessment (Abnormal Involuntary Movement Scale [AIMS]) in participants…
  • 2019 International Congress

    Long-Term Treatment With Deutetrabenazine Is Associated With Continued Improvement in Tardive Dyskinesia: Results From an Open-Label Extension Study

    R. Hauser, H. Barkay, H. Fernandez, S. Factor, J. Jimenez-Shahed, N. Gross, M. Gordon, JM. Savola, K. Anderson (Tampa, FL, USA)

    Objective: To evaluate long-term efficacy of deutetrabenazine in patients with tardive dyskinesia (TD) by examining the change from baseline in Abnormal Involuntary Movement Scale (AIMS)…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • …
  • 8
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley